Advertisement
Canada markets closed
  • S&P/TSX

    22,059.03
    -184.97 (-0.83%)
     
  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     
  • DOW

    39,375.87
    +67.87 (+0.17%)
     
  • CAD/USD

    0.7334
    +0.0002 (+0.02%)
     
  • CRUDE OIL

    82.79
    -0.37 (-0.44%)
     
  • Bitcoin CAD

    74,975.54
    -4,620.02 (-5.80%)
     
  • CMC Crypto 200

    1,142.17
    -66.52 (-5.50%)
     
  • GOLD FUTURES

    2,394.40
    -3.30 (-0.14%)
     
  • RUSSELL 2000

    2,026.73
    -9.89 (-0.49%)
     
  • 10-Yr Bond

    4.2720
    -0.0830 (-1.91%)
     
  • NASDAQ futures

    20,594.50
    -26.25 (-0.13%)
     
  • VOLATILITY

    12.48
    +0.22 (+1.79%)
     
  • FTSE

    8,203.93
    -37.33 (-0.45%)
     
  • NIKKEI 225

    40,917.77
    +5.40 (+0.01%)
     
  • CAD/EUR

    0.6770
    +0.0008 (+0.12%)
     

These Analysts Think Alfen N.V.'s (AMS:ALFEN) Sales Are Under Threat

The latest analyst coverage could presage a bad day for Alfen N.V. (AMS:ALFEN), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Revenue estimates were cut sharply as analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well. Surprisingly the share price has been buoyant, rising 10% to €18.50 in the past 7 days. Whether the downgrade will have a negative impact on demand for shares is yet to be seen.

Following the downgrade, the current consensus from Alfen's ten analysts is for revenues of €531m in 2024 which - if met - would reflect a satisfactory 5.3% increase on its sales over the past 12 months. Statutory earnings per share are anticipated to plummet 77% to €0.31 in the same period. Before this latest update, the analysts had been forecasting revenues of €593m and earnings per share (EPS) of €1.57 in 2024. Indeed, we can see that the analysts are a lot more bearish about Alfen's prospects, administering a substantial drop in revenue estimates and slashing their EPS estimates to boot.

View our latest analysis for Alfen

earnings-and-revenue-growth
earnings-and-revenue-growth

The consensus price target fell 43% to €28.65, with the weaker earnings outlook clearly leading analyst valuation estimates.

ADVERTISEMENT

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's pretty clear that there is an expectation that Alfen's revenue growth will slow down substantially, with revenues to the end of 2024 expected to display 5.3% growth on an annualised basis. This is compared to a historical growth rate of 32% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 6.6% annually. Factoring in the forecast slowdown in growth, it seems obvious that Alfen is also expected to grow slower than other industry participants.

The Bottom Line

The biggest issue in the new estimates is that analysts have reduced their earnings per share estimates, suggesting business headwinds lay ahead for Alfen. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. The consensus price target fell measurably, with analysts seemingly not reassured by recent business developments, leading to a lower estimate of Alfen's future valuation. Given the stark change in sentiment, we'd understand if investors became more cautious on Alfen after today.

After a downgrade like this, it's pretty clear that previous forecasts were too optimistic. What's more, we've spotted several possible issues with Alfen's business, like its declining profit margins. Learn more, and discover the 1 other warning sign we've identified, for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com